Trophic effect in MCF-7 cells of ERα17p, a peptide corresponding to a platform regulatory motif of the estrogen receptor α-Underlying mechanisms

Journal of Steroid Biochemistry and Molecular Biology

Volumn 109, Issue 1-2, 2008, Pages 138-149

  Gallo, Dominique ^a   Haddad, Iman ^b   Duvillier, Hugues ^a   Jacquemotte, Françoise ^c   Laïos, Ioanna ^a   Laurent, Guy ^d   Jacquot, Yves ^e   Vinh, Joëlle ^b   Leclercq, Guy ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b CNRS   (France)

^c Meurice Institute   (Belgium)

^d UNIVERSITY OF MONS   (Belgium)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Breast cancer; ER 17p; Estrogen receptor ; Hsp70; Synthetic peptide

Indexed keywords

ESTROGEN RECEPTOR ALPHA; HEAT SHOCK PROTEIN 70;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; COMPETITIVE INHIBITION; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; GENE REPRESSION; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HORMONE ACTION; HORMONE RESPONSE; HUMAN; HUMAN CELL; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PROTEIN MOTIF; RECEPTOR DOWN REGULATION;

EID: 40849145717     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.12.012     Document Type: Article

References (70)

1. Kumar V., Green S., Stack G., Berry M., Jin J.R., and Chambon P. Functional domains of the human estrogen receptor. Cell 51 (1987) 941-951
2. Webster N.J., Green S., Jin J.R., and Chambon P. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54 (1988) 199-207
3. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E., and Chambon P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59 (1989) 477-487
4. Norris J.D., Fan D., Kerner S.A., and McDonnell D.P. Identification of a third autonomous activation domain within the human estrogen receptor. Mol. Endocrinol. 11 (1997) 747-754
5. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., and Scanlan T.S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277 (1997) 1508-1510
6. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., and Webb P. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74 (2000) 311-317
7. Saville B., Wormke M., Wang F., Nguyen T., Enmark E., Kuiper G., Gustafsson J.A., and Safe S. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J. Biol. Chem. 275 (2000) 5379-5387
8. Jensen E.V., Block G.E., Smith S., Kyser K., and DeSombre E.R. Estrogen receptors and breast cancer response to adrenalectomy. Natl. Cancer Inst. Monogr. 34 (1971) 55-70
9. Ali S., and Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2 (2002) 101-112
10. Savkur R.S., and Burris T.P. The coactivator LXXLL nuclear receptor recognition motif. J. Pept. Res. 63 (2004) 207-212
11. Leduc A.M., Trent J.O., Wittliff J.L., Bramlett K.S., Briggs S.L., Chirgadze N.Y., Wang Y., Burris T.P., and Spatola A.F. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 11273-11278
12. Rodriguez A.L., Tamrazi A., Collins M.L., and Katzenellenbogen J.A. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding. J. Med. Chem. 47 (2004) 600-611
13. Norris J.D., Paige L.A., Christensen D.J., Chang C.Y., Huacani M.R., Fan D., Hamilton P.T., Fowlkes D.M., and McDonnell D.P. Peptide antagonists of the human estrogen receptor. Science 285 (1999) 744-746
14. Connor C.E., Norris J.D., Broadwater G., Willson T.M., Gottardis M.M., Dewhirst M.W., and McDonnell D.P. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res. 61 (2001) 2917-2922
15. Geistlinger T.R., and Guy R.K. Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2. J. Am. Chem. Soc. 125 (2003) 6852-6853
16. McDonnell D.P., Chang C.Y., and Norris J.D. Development of peptide antagonists that target estrogen receptor-cofactor interactions. J. Steroid Biochem. Mol. Biol. 74 (2000) 327-335
17. Galande A.K., Bramlett K.S., Burris T.P., Wittliff J.L., and Spatola A.F. Thioether side chain cyclization for helical peptide formation: inhibitors of estrogen receptor-coactivator interactions. J. Pept. Res. 63 (2004) 297-302
18. Galande A.K., Bramlett K.S., Trent J.O., Burris T.P., Wittliff J.L., and Spatola A.F. Potent inhibitors of LXXLL-based protein-protein interactions. Chembiochemistry 6 (2005) 1991-1998
19. Zhou H.B., Collins M.L., Gunther J.R., Comninos J.S., and Katzenellenbogen J.A. Bicyclo[2,2,2]octanes: close structural mimics of the nuclear receptor-binding motif of steroid receptor coactivators. Bioorg. Med. Chem. Lett. 17 (2007) 4118-4122
20. Wang R.A., Mazumdar A., Vadlamudi R.K., and Kumar R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J. 21 (2002) 5437-5447
21. Lee H., and Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol. Cell. Biol. 22 (2002) 5835-5845
22. Wang C., Fu M., Angeletti R.H., Siconolfi-Baez L., Reutens A.T., Albanese C., Lisanti M.P., Katzenellenbogen B.S., Kato S., Hopp T., Fuqua S.A., Lopez G.N., Kushner P.J., and Pestell R.G. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem. 276 (2001) 18375-18383
23. Cui Y., Zhang M., Pestell R., Curran E.M., Welshons W.V., and Fuqua S.A. Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res. 64 (2004) 9199-9208
24. Sentis S., Le R.M., Bianchin C., Rostan M.C., and Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol. Endocrinol. 19 (2005) 2671-2684
25. Eakin C.M., Maccoss M.J., Finney G.L., and Klevit R.E. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 5794-5799
26. Heine G.F., and Parvin J.D. BRCA1 control of steroid receptor ubiquitination. Sci. STKE. 2007 (2007) pe34
27. 2+-calmodulin. Mol. Endocrinol. 2 (1988) 167-174
28. Bouhoute A., and Leclercq G. Modulation of estradiol and DNA binding to estrogen receptor upon association with calmodulin. Biochem. Biophys. Res. Commun. 208 (1995) 748-755
29. 2+/calmodulin. J. Biol. Chem. 280 (2005) 13097-13104
30. Gallo D., Jacquemotte F., Cleeren A., Laios I., Hadiy S., Rowlands M.G., Caille O., Nonclercq D., Laurent G., Jacquot Y., and Leclercq G. Calmodulin-independent, agonistic properties of a peptide containing the calmodulin binding site of estrogen receptor alpha. Mol. Cell. Endocrinol. 268 (2007) 37-49
31. Li L., and Sacks D.B. Functional interactions between calmodulin and estrogen receptor-alpha. Cell. Signal. 19 (2007) 439-443
32. Li L., Li Z., Howley P.M., and Sacks D.B. E6AP and calmodulin reciprocally regulate estrogen receptor stability. J. Biol. Chem. 281 (2006) 1978-1985
33. Picard D., Kumar V., Chambon P., and Yamamoto K.R. Signal transduction by steroid hormones: nuclear localization is differentially regulated in estrogen and glucocorticoid receptors. Cell Regul. 1 (1990) 291-299
34. Ylikomi T., Bocquel M.T., Berry M., Gronemeyer H., and Chambon P. Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors. EMBO J. 11 (1992) 3681-3694
35. Seielstad D.A., Carlson K.E., Kushner P.J., Greene G.L., and Katzenellenbogen J.A. Analysis of the structural core of the human estrogen receptor ligand binding domain by selective proteolysis/mass spectrometric analysis. Biochemistry 34 (1995) 12605-12615
36. Gallo D., Jacquot Y., Cleeren A., Jacquemotte F., Laios I., Laurent G., and Leclercq G. Molecular basis of agonistic activity of ERalpha17p, a synthetic peptide corresponding to a sequence located at the N-terminal part of the estrogen receptor alpha ligand binding domain. Lett. Drug Des. Discov. 4 (2007) 346-355
37. Haelens A., Tanner T., Denayer S., Callewaert L., and Claessens F. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res. 67 (2007) 4514-4523
38. Jacquot Y., Gallo D., and Leclercq G. Estrogen receptor alpha-identification by a modeling approach of a potential polyproline II recognizing domain within the AF-2 region of the receptor that would play a role of prime importance in its mechanism of action. J. Steroid Biochem. Mol. Biol. 104 (2007) 1-10
39. Warnmark A., Treuter E., Gustafsson J.A., Hubbard R.E., Brzozowski A.M., and Pike A.C. Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha. J. Biol. Chem. 277 (2002) 21862-21868
40. Kong E.H., Heldring N., Gustafsson J.A., Treuter E., Hubbard R.E., and Pike A.C. Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3593-3598
41. Jensen E.V., Suzuki T., Numata M., Smith S., and DeSombre E.R. Estrogen-binding substances of target tissues. Steroids 13 (1969) 417-427
42. Sarff M., and Gorski J. Control of estrogen binding protein concentration under basal conditions and after estrogen administration. Biochemistry 10 (1971) 2557-2563
43. Atherton E., and Sheppard R.C. Solid Phase Peptide Synthesis: a Practical Approach (1989), IRL Press, Oxford
44. Journe F., Chaboteaux C., Dumon J.C., Leclercq G., Laurent G., and Body J.J. Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells. Br. J. Cancer 91 (2004) 1703-1710
45. Compton J. Nucleic acid sequence-based amplification. Nature 350 (1991) 91-92
46. Verjat T., Cerrato E., Jacobs M., Leissner P., and Mougin B. Multiparametric duplex real-time nucleic acid sequence-based amplification assay for mRNA profiling. Biotechniques 37 (2004) 476-481
47. Laios I., Journe F., Laurent G., Nonclercq D., Toillon R.A., Seo H.S., and Leclercq G. Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens. J. Steroid Biochem. Mol. Biol. 87 (2003) 207-221
48. Shevchenko A., Wilm M., Vorm O., and Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68 (1996) 850-858
49. Kitagawa M., Higashi H., Jung H.K., Suzuki-Takahashi I., Ikeda M., Tamai K., Kato J., Segawa K., Yoshida E., Nishimura S., and Taya Y. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 15 (1996) 7060-7069
50. Jensen E.V., Cheng G., Palmieri C., Saji S., Makela S., Van N.S., Wahlstrom T., Warner M., Coombes R.C., and Gustafsson J.A. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 15197-15202
51. Leclercq G., Lacroix M., Laios I., and Laurent G. Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells. Curr. Cancer Drug Targets 6 (2006) 39-64
52. Chu I., Arnaout A., Loiseau S., Sun J., Seth A., McMahon C., Chun K., Hennessy B., Mills G.B., Nawaz Z., and Slingerland J.M. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J. Clin. Invest. 117 (2007) 2205-2215
53. El Khissiin K.A., and Leclercq G. Implication of proteasome in estrogen receptor degradation. FEBS Lett. 448 (1999) 160-166
54. Marsaud V., Gougelet A., Maillard S., and Renoir J.M. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol. Endocrinol. 17 (2003) 2013-2027
55. Laios I., Journe F., Nonclercq D., Vidal D.S., Toillon R.A., Laurent G., and Leclercq G. Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells. J. Steroid Biochem. Mol. Biol. 94 (2005) 347-359
56. Wegele H., Muller L., and Buchner J. Hsp70 and Hsp90-a relay team for protein folding. Rev. Physiol. Biochem. Pharmacol. 151 (2004) 1-44
57. Picard D. Chaperoning steroid hormone action. Trends Endocrinol. Metab. 17 (2006) 229-235
58. Ogawa S., Oishi H., Mezaki Y., Kouzu-Fujita M., Matsuyama R., Nakagomi M., Mori E., Murayama E., Nagasawa H., Kitagawa H., Yanagisawa J., Yano T., and Kato S. Repressive domain of unliganded human estrogen receptor alpha associates with Hsc70. Genes Cells 10 (2005) 1095-1102
59. Rudiger S., Germeroth L., Schneider-Mergener J., and Bukau B. Substrate specificity of the DNAk chaperone determined by screening cellulose-bound peptide libraries. EMBO J. 16 (1997) 1501-1507
60. Chen Z., Kurt N., Rajagopalan S., and Cavagnero S. Secondary structure mapping of DNAk-bound protein fragments: chain helicity and local helix unwinding at the binding site. Biochemistry 45 (2006) 12325-12333
61. Fan M., Park A., and Nephew K.P. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol. Endocrinol. 19 (2005) 2901-2914
62. Tateishi Y., Kawabe Y., Chiba T., Murata S., Ichikawa K., Murayama A., Tanaka K., Baba T., Kato S., and Yanagisawa J. Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J. 23 (2004) 4813-4823
63. Nawaz Z., Lonard D.M., Smith C.L., Lev-Lehman E., Tsai S.Y., Tsai M.J., and O'Malley B.W. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol. Cell. Biol. 19 (1999) 1182-1189
64. Khan O.Y., Fu G., Ismail A., Srinivasan S., Cao X., Tu Y., Lu S., and Nawaz Z. Multifunction steroid receptor coactivator, E6-associated protein, is involved in development of the prostate gland. Mol. Endocrinol. 20 (2006) 544-559
65. Saji S., Okumura N., Eguchi H., Nakashima S., Suzuki A., Toi M., Nozawa Y., Saji S., and Hayashi S. MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Biochem. Biophys. Res. Commun. 281 (2001) 259-265
66. Nakajima A., Maruyama S., Bohgaki M., Miyajima N., Tsukiyama T., Sakuragi N., and Hatakeyama S. Ligand-dependent transcription of estrogen receptor alpha is mediated by the ubiquitin ligase EFP. Biochem. Biophys. Res. Commun. 357 (2007) 245-251
67. Fuqua S.A., Wiltschke C., Zhang Q.X., Borg A., Castles C.G., Friedrichs W.E., Hopp T., Hilsenbeck S., Mohsin S., O'Connell P., and Allred D.C. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 60 (2000) 4026-4029
68. El Khissiin K.A., Journe F., Laios I., Seo H.S., and Leclercq G. Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells. Steroids 65 (2000) 903-913
69. Seo H.S., DeNardo D.G., Jacquot Y., Laios I., Vidal D.S., Zambrana C.R., Leclercq G., and Brown P.H. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res. Treat. 99 (2006) 121-134
70. Laios I., Cleeren A., Leclercq G., Nonclercq D., Laurent G., Schlenk M., Wellner A., and Gust R. Effects of (R,S)/(S,R)-4,5-bis(2-chloro-4-hydroxyphenyl)-2-imidazolines and (R,S)/(S,R)-2,3-bis(2-chloro-4-hydroxyphenyl)piperazines on estrogen receptor alpha level and transcriptional activity in MCF-7 cells. Biochem. Pharmacol. 74 (2007) 1029-1038